GLP-1 Medications and Bowel Incontinence
GLP-1 receptor agonists, including retatrutide, are NOT associated with causing fecal incontinence. In fact, emerging evidence suggests they may actually help reduce diarrhea and improve bowel control in certain conditions.
Key Evidence on GI Effects
The most comprehensive recent meta-analysis of GLP-1 receptor agonists found no increased risk of fecal incontinence 1. This 2025 systematic review of 55 randomized controlled trials involving over 106,000 participants specifically evaluated serious gastrointestinal adverse events and found that GLP-1RAs increased only the risk of:
- Cholelithiasis (gallstones)
- GERD (gastroesophageal reflux disease)
Bowel incontinence was not identified as an adverse event in this rigorous analysis 1.
What GI Side Effects Actually Occur
The gastrointestinal adverse events that DO occur with GLP-1 medications are 2, 3:
- Nausea (most common)
- Vomiting
- Diarrhea
- Constipation
These are typically mild-to-moderate in severity and occur in 47-84% of patients (versus 13-63% with placebo). Importantly, these symptoms represent transient GI upset, not loss of bowel control 2.
Retatrutide-Specific Data
For retatrutide specifically, the phase 2 trial showed that mild-to-moderate GI adverse events (nausea, diarrhea, vomiting, constipation) occurred in 35% of retatrutide-treated patients versus 13% with placebo 3. Again, fecal incontinence was not reported as an adverse event across any dose level (0.5 mg to 12 mg weekly) 3.
Potential Protective Effects
Interestingly, there is emerging evidence that GLP-1RAs may actually help certain bowel conditions:
A 2025 study demonstrated that liraglutide was superior to standard bile acid sequestration therapy for treating bile acid diarrhea, a condition characterized by diarrhea, urgency, and fecal incontinence 4
Genetic evidence from 2026 suggests GLP-1RAs may have a protective effect against paralytic ileus 5
GLP-1RAs are being studied for managing high stoma output, with reductions up to 50% in output volume 6
Clinical Bottom Line
You can reassure patients that fecal incontinence is not a recognized side effect of GLP-1 medications or retatrutide. The gastrointestinal effects that do occur—nausea, vomiting, diarrhea, and constipation—represent altered GI motility and secretion, not loss of sphincter control or bowel continence.
Important Caveat
While diarrhea can occur as a side effect in some patients, this represents increased stool frequency and liquidity, not involuntary loss of bowel control. If a patient develops severe diarrhea on these medications, standard antidiarrheal management (loperamide, dietary modification) should be employed 7, but this is distinct from true fecal incontinence requiring specialized evaluation.